Mapping analysis to predict SF-6D utilities from health outcomes in people with focal epilepsy

Flint, India; Medjedovic, Jasmina; O’Flaherty, Ewa Drogon; Álvarez-Barón, Elena; Thangavelu, Karthinathan; Savić, Nataša; Meunier, Aurélie; Longworth, Louise

doi:10.1007/s10198-022-01519-w

Cited by 2 publications

(6 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We compared our findings with those of studies conducted in different countries. 34 , 35 The mean utility values (0.584) of persons living with epilepsy in developed countries (the United Kingdom, France, Italy, Germany, and Spain) were higher than those of the current study. 34 The pooled estimate of health utility values in stroke survivors for the SF-6D was reported as 0.70 (95% confidence interval [CI] 0.63–0.78; 2 studies), 35 which is higher than the utility values for the Nigerian stroke survivors.…”

Section: Discussioncontrasting

confidence: 77%

“… 34 , 35 The mean utility values (0.584) of persons living with epilepsy in developed countries (the United Kingdom, France, Italy, Germany, and Spain) were higher than those of the current study. 34 The pooled estimate of health utility values in stroke survivors for the SF-6D was reported as 0.70 (95% confidence interval [CI] 0.63–0.78; 2 studies), 35 which is higher than the utility values for the Nigerian stroke survivors. The use of a different type of tool and the severity of the condition could be the reasons for the variation of health state utility values.…”

Section: Discussioncontrasting

confidence: 77%

“…For example, the study sample included in the study conducted in the United Kingdom, France, Italy, Germany, and Spain was people with less severe epilepsy. 34 Previous studies also demonstrated the presence of variability in utilities between measurement techniques. 34 , 36 Therefore, when measuring utilities, it is important to recognize that utility scores for the same health state could vary depending on which technique is used and the severity of the condition.…”

Section: Discussionmentioning

confidence: 94%

See 2 more Smart Citations

Estimating Utility Values for Health States of Nigerian Individuals with Stroke or Epilepsy Using the SF-36: A Brief Report on the Results of a Cross-Sectional Survey

Gebrye,

Akosile,

Okoye

et al. 2024

MDM Policy & Practice

View full text Add to dashboard Cite

Background. Stroke and epilepsy are the most common neurologic conditions affecting individuals. The Short Form Six-Dimension Health Index (SF-6D) is a preference-based measure of health developed to estimate utility values from the SF-36. This study estimated utility values for health states of Nigerian individuals with stroke or epilepsy using the SF-36. Methods. SF-36 responses from 125 and 69 individuals with stroke and persons with epilepsy, respectively, were transformed into health state utility values using the SF-6D algorithm. The Excel program developed by Brazier and colleagues was used to generate the SF-6D utility score estimated using a set of parametric preference weights. The health state utility values were determined using ordinal health state and standard gamble valuation techniques. Results. Mean ( s) ages of the stroke and epilepsy participants were 63.1 (11) and 39.6 (16) y, respectively. The mean ( s) utility scores for stroke and epilepsy were 0.52 (0.10) and 0.65 (0.1) for standard gamble and 0.48 (0.13) and 0.68 (0.11), respectively, using the ordinal health state paradigm. The mean ( s) utility of stroke (female = 0.46 [0.15]; male = 0.50 [0.12]) and epilepsy (female = 0.65 [0.13], male = 0.69 [0.11]) participants were reported. The mean ( s) annual episodes of seizure was 18.7 (39). Conclusions. To our knowledge, this is the first study to suggest that females with stroke and those with epilepsy considered their health to be poorer than that of their male counterparts. The significance of our findings is that they may be helpful for researchers, policy makers, and clinicians by providing input into economic evaluations to facilitate resource allocation for stroke survivors and people living with epilepsy to improve their health outcomes and reduce the huge burden associated with the conditions. Highlight We estimated a health state utility value for stroke and epilepsy to aid researchers and public health policy makers in conducting health economic analysis and outcomes research.

show abstract

Section: Discussioncontrasting

confidence: 77%

Section: Discussioncontrasting

confidence: 77%

Section: Discussionmentioning

confidence: 94%

See 1 more Smart Citation

Estimating Utility Values for Health States of Nigerian Individuals with Stroke or Epilepsy Using the SF-36: A Brief Report on the Results of a Cross-Sectional Survey

Gebrye,

Akosile,

Okoye

et al. 2024

MDM Policy & Practice

View full text Add to dashboard Cite

show abstract

“…Flint et al, developed a mapping algorithm to predict SF-6D values in adults with focal-onset seizures for use in economic evaluations of CNB [ 100 ]. This preference-based measure of health-related quality of life can assess six dimensions of health status, including physical functioning, role limitation, social functioning, pain, mental functioning, and vitality [ 101 ].…”

Section: Discussionmentioning

confidence: 99%

“…This preference-based measure of health-related quality of life can assess six dimensions of health status, including physical functioning, role limitation, social functioning, pain, mental functioning, and vitality [ 101 ]. The authors found that the mapping algorithm proposed may predict SF-6D values from clinical outcomes in people with epilepsy [ 100 ]. Therefore, researchers can use outcome data from clinical trials with CNB to facilitate cost–utility analysis.…”

Section: Discussionmentioning

confidence: 99%

Cenobamate (YKP3089) and Drug-Resistant Epilepsy: A Review of the Literature

Rissardo,

Fornari Caprara

2023

Medicina

View full text Add to dashboard Cite

Cenobamate (CNB), ([(R)-1-(2-chlorophenyl)-2-(2H-tetrazol-2-yl)ethyl], is a novel tetrazole alkyl carbamate derivative. In November 2019, the Food and Drug Administration approved Xcopri®, marketed by SK Life Science Inc., (Paramus, NJ, USA) for adult focal seizures. The European Medicines Agency approved Ontozry® by Arvelle Therapeutics Netherlands B.V.(Amsterdam, The Neatherlands) in March 2021. Cenobamate is a medication that could potentially change the perspectives regarding the management and prognosis of refractory epilepsy. In this way, this study aims to review the literature on CNB’s pharmacological properties, pharmacokinetics, efficacy, and safety. CNB is a highly effective drug in managing focal onset seizures, with more than twenty percent of individuals with drug-resistant epilepsy achieving seizure freedom. This finding is remarkable in the antiseizure medication literature. The mechanism of action of CNB is still poorly understood, but it is associated with transient and persistent sodium currents and GABAergic neurotransmission. In animal studies, CNB showed sustained efficacy and potency in the 6 Hz test regardless of the stimulus intensity. CNB was revealed to be the most cost-effective drug among different third-generation antiseizure medications. Also, CNB could have neuroprotective effects. However, there are still concerns regarding its potential for abuse and suicidality risk, which future studies should clearly assess, after which protocols should be changed. The major drawback of CNB therapy is the slow and complex titration and maintenance phases preventing the wide use of this new agent in clinical practice.

show abstract

Mapping analysis to predict SF-6D utilities from health outcomes in people with focal epilepsy

Cited by 2 publications

References 35 publications

Estimating Utility Values for Health States of Nigerian Individuals with Stroke or Epilepsy Using the SF-36: A Brief Report on the Results of a Cross-Sectional Survey

Estimating Utility Values for Health States of Nigerian Individuals with Stroke or Epilepsy Using the SF-36: A Brief Report on the Results of a Cross-Sectional Survey

Cenobamate (YKP3089) and Drug-Resistant Epilepsy: A Review of the Literature

Contact Info

Product

Resources

About